fashion -WSS

fashion

author：fashion 2025-08-12 09:13:14 - browse：8

Fatty liver foregrounds arteries and veins surrounded by red blood cells — health coverage from STAT — Adobe

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： How to save health care price transparency rules

explore

WSS

Commercial surrogacy can be ethical, despite pope’s claims

Boston's new lab space is opening empty

The real point of Kenneth Smith’s execution by nitrogen gas

Ebola: Gilead Sciences antiviral shows promise as new treatment

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

EPA limits use of carcinogenic gas for sterilizing medical devices

knowledge

fashion

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Pushing for an NIH office for post

Continuity nursing helped my family in our darkest PICU moments

Amid AI frenzy, a top HHS official's quest to create safeguards

Wildfire smoke exposes gaps in outdoor worker protections

Time to name cancers by genetics, not organ of origin, expert says

Bright Health sells Medicare Advantage business to Molina

Juul spent big to court Black leaders to promote its e

Virginia high school admissions case could be legal follow

Steward Health Care Massachusetts hospitals face fiscal disaster

leisure time

UCLA team creates talking throat patch for voice disorders

Ebola: Gilead Sciences antiviral shows promise as new treatment

Congressmen charge Covid hearing ‘could have been an email’

EPA limits use of carcinogenic gas for sterilizing medical devices

Change Healthcare outage fallout shows need for new oversight

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

explore

focus

focus

hotspot